Home
Search
Human Health

Drug Development, Review & Lifecycle Management

Before a therapy is approved for delivery to patients a lot of hard work and research goes into demonstrating that the therapy is safe, effective, and high quality. We work to promote a regulatory environment that supports safe and efficient development and approval of therapies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.

Drug Development and Clinical Trial Process
Drug Development and Clinical Trials Process
Learn More

 

Insights
Browse all insights
Researcher
An Update on Clinical Development and Therapeutic Company Funding and Deals
Good Trouble for Good Medicine
Good Trouble for Good Medicine
BIO
Marking Rare Disease Day 2021
News
Browse all news
BIO Submits Comments on FDA Manufacturing, Supply Chain, and Inspections Guidances & Report
July 16, 2021
BIO Comments on FDA’s Draft Guidance on Human Gene Therapy for Neurodegenerative Diseases
April 6, 2021
BIO Comments on FDA’s Public Meeting Announcement: Best Practices for Development and Application of Disease Progression Models
March 26, 2021
BIO Welcomes Collaboration With New HHS, USTR Leaders
March 18, 2021
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
BIO Submits Comments on FDA Manufacturing, Supply Chain, and Inspections Guidances & Report
July 16, 2021
On Wednesday, July 14th, BIO submitted comments on FDA’s Guidances: 1) Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency Guidance; 2) Updated Manufacturing, Supply Chain, and Drug and Biological Product Inspections…
BIO Comments on FDA’s Draft Guidance on Human Gene Therapy for Neurodegenerative Diseases
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers many critical development issues for gene therapies,…
BIO Comments on FDA’s Public Meeting Announcement: Best Practices for Development and Application of Disease Progression Models
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking input from stakeholders on three key areas,…
Join BIOAction
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction